Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
Aaqib H MalikSrikanth YandrapalliWilbert S AronowJulio A PanzaHoward A CooperPublished in: Heart (British Cardiac Society) (2019)
NOACs performed better than warfarin for a reduction in SSE, MI and ICH in patients with VHD. Individually NOACs performed similarly to each other except for an increased risk of ICH and major bleeding with rivaroxaban and a reduced risk of major bleeding with edoxaban 30 mg. In patients with a BPHV, results with NOACs seem similar to those with warfarin and this needs to be further explored in larger studies.
Keyphrases
- oral anticoagulants
- atrial fibrillation
- aortic valve
- aortic valve replacement
- catheter ablation
- left atrial
- direct oral anticoagulants
- left atrial appendage
- heart failure
- venous thromboembolism
- mitral valve
- percutaneous coronary intervention
- transcatheter aortic valve replacement
- pulmonary hypertension
- transcatheter aortic valve implantation
- aortic stenosis
- acute coronary syndrome
- left ventricular
- ejection fraction